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Multielectrode arrays (MEAs) are electrical devices that transduce
(record/deliver) cellular voltage signals. Commercially available
MEAs are expensive and here we provide proof of concept for the
application of an additive manufacturing approach to prepare
inexpensive MEAs and demonstrate their ability to interact with
brain tissue ex vivo.
Electrodes (optionally in arrays [e.g. microelectrode/multielectrode
arrays]) can record/stimulate electrical signals to/from biological
samples.1–8 Excited muscle cells and neurons enable the flow of
ion currents through their cell membranes via voltage-gated ion
channels. Recording electrodes convert environmental voltages
carried by ions into electronic currents, and stimulating electrodes
convert electronic currents into ionic currents in the environment
(e.g. medium/tissue). The voltage differences inside/outside cells
trigger the voltage-gated ion channels in the cell membranes of
muscle cells and neurons to depolarize, and this depolarization
triggers a twitch in muscle cells or an action potential in neurons.9
MEAs to record/stimulate electrical signals have been designed
for in vitro,9–15 ex vivo16–20 and in vivo applications,3,4,21–24 where
the signal’s magnitude and shape are governed by the specific
properties of the experimental paradigm: circuit design, electrode
dimensions/impedance/material, quality of cell-electrode contact,
properties of the medium/tissue (capacitance, conductivity and
homogeneity), and signal processing. There are commercially
available MEAs (typically metal-/alloy-based)15,25–28 that are
manufactured by standard methods, such as lithography29 or
electrochemical micromachining,30 however, they are expensive.
MEAs can be produced from a variety of conductive materials
(e.g. carbon nanotubes [CNTs],31,32 gold, indium–tin oxide, iridium
oxide, nickel, platinum, silicon, steel),3,4,23,24,33 deposited on a non-
conductive support substrate (e.g. glass, polydimethylsiloxane
[PDMS]), with appropriately positioned insulation materials (e.g.
parylene, silicon nitride, SU-8 epoxy resin and polyimide). The
charge transfer properties of the electrodes depends on their
surface area and the thickness of the electrode–electrolyte double
layer, and the electrode surfaces may be modified (e.g. ablated/
coated) to produce electrodes with low impedances to ensure high
signal-to-noise ratios.34,35
Additive manufacturing (AM) techniques are capable of
producing components for electronic applications.36–39 The
aim of this study was to use AM methods to produce inexpensive
MEAs (arrays of at least six by six electrodes) with non-exposed
tracks for the purpose of exciting nerve tissue and validate their
efficacy in electrical signal transduction in an ex vivo model
system (mouse brain slices). This AM method enables other
researchers to produce bespoke MEAs designed to suit the
specific requirements of the paradigms/samples to be studied.
A variety of AM methods can be employed to produce
MEAs,36–40 and here MEAs were produced via the injection of
conductive materials into substrates fabricated using AM.41 Pre-
liminary prototyping was carried out with polylactide (PLA) fila-
ment using a Z-Morph 2SX Multi-Tool 3D Printer, an Ultimaker 2+
and a Stratasys J750, of which the Stratasys J750 produced the
highest fidelity parts with minimal/no porosity (Fig. S1 and Tables
S1, S2, ESI†). Consequently, a Stratasys J750 was used to print MEA
substrates with hollow channels that were subsequently filled with
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conductive materials to create electrode channels. Wu and
colleagues reported that filling channels with widths less than
400 mm in analogous structures was often unsuccessful,36 con-
sequently the dimensions of the channels in the computer aided
design (CAD) model were greater than 400 mm (Fig. 1A and B).42
Attempts to produce the non-conductive MEA supports with
tracks to be filled with conductive materials led to the conclusion
that splitting the MEA in half along the horizontal axis and filling
the two halves separately should allow for ease of manufacture
without compromising functionality in accordance with the
prototype specification in Table S3 (ESI†). Aligning the top and
bottom accurately with planar halves was challenging due to the
lack of a guiding mechanism, resulting in the tendency of the
halves to slide out of position when pressure was applied. Conse-
quently, recesses on the bottom half and extrusions on the top
half in the corresponding positions were employed to mate the
halves together, ensure alignment of the electrodes and ensure the
MEAs could be handled easily in the laboratory (Fig. 1A and B),
using the process outlined in Fig. 1C, and described in a step-by-
step fashion for the silver contact MEAs in Table S4 (ESI†) and the
CNTs/PDMS contact MEAs in Table S5 (ESI†).
It is possible to prepare MEAs with silver-based electrodes
using a commercially available paste to fill the channels
electrode tracks. The paste was too viscous to be injected easily,
necessitating the addition of a dispersing agent (either acetone
or a-terpineol, the latter of which was listed as the dispersant in
the commercially available paste). It was observed that formu-
lations with a-terpineol were smoother and more consistent
facilitating easier transfer from mixing container into syringes
for subsequent injection, and its lower volatility than acetone
enabled storage of batches for a few days. The conductive
channels in the MEA structures produced after evaporation of
all of the dispersing agents were composed of silver microparticles
(20 wt% o5 mm in diameter) and nanoparticles (80 wt% ca.
200 nm in diameter). The surface of the entire MEAs were sanded
and the individual electrodes were painted with silver paint,
yielding silver MEAs (Fig. S2, ESI†). It is possible to prepare MEAs
with electrodes composed of composites of CNTs and PDMS by
injection of a degassed paste composed of CNTs suspended in
uncured silicone elastomer into the MEA channels (Fig. S3, ESI†),
followed by curing, yielding CNTs/PDMS MEAs. In the long term
we expect the manual channel filling process to be automated to
increase the production rate, thereby facilitating rapid optimisa-
tion of the prototype MEAs for specific applications and poten-
tially enabling their production (batch/mass) by other methods.
PLA is an FDA-approved polymer that is generally recognized
as safe (GRAS), and we conducted in silico toxicity screening of
the other components utilised in the production of the proto-
type MEAs (Table S6, ESI†) using commercially available software
(Derek Nexus43 (Derek Nexus: v. 6.0.1, Nexus: 2.2.2) and Sarah
Nexus44 (Sarah Nexus: v. 3.0.0, Sarah Model: 2.0) to assess
potential hazards (Derek identifies structural alerts for several
endpoints and Sarah is a statistical-based model focused on
mutagenicity only) during production and use, that we have
previously applied to materials for bioelectronic applications.45,46
For the silver contact MEAs Derek Nexus suggested some potential
for a-terpineol to induce skin sensitization,47–49 and to be nephro-
toxic (due to the presence of the terpenoid and tertiary alcohol in
the structure, respectively), Sarah Nexus suggested that acetone
may be mutagenic (6% confidence), and risks from these solvents
can be diminished by production in a controlled environment
(e.g. fume hood) and vacuum drying. The in silico studies did not
identify silver as a sensitiser or mutagen (the in silico models are
usually developed for and based on data for organic compounds),
however, other studies have identified allergenic/irritant res-
ponses and toxicity (genotoxic, hepatic, renal, neurological,
and hematological effects) dependent on the form of silver (ions,
metallic, or nanoparticle) and dose of silver exposure.50 For the
CNTs/PDMS contact MEAs Derek Nexus suggested some
potential for the CNTs to induce skin sensitization due to the
presence of conjugated dienes in their structures51 (and other
studies have reported a variety of toxic effects resulting from
CNTs);52–60 PDMS may be hepatotoxic and nephrotoxic due to
the organosilicon and ether functionalities present in the
PDMS,61 respectively (and other studies have reported the toxi-
city of siloxanes in various scenarios).62–64 In the case of the
materials described in this work, it is possible to contemplate
their use as MEAs that would be removed after short term
exposure in vivo, or use for in vitro and ex vivo studies, followed
by safe disposal.
Fig. 1 (A) CAD model of MEA including cutouts on the bottom half and
extrusions on the top half in the corresponding positions to clip the halves
together, ensure alignment of the electrodes and ensure the MEA could be
handled easily in the laboratory. (B) Top view of CAD model of MEA.
(C) Summary of the MEA production process. (D) Photograph of a silver
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A 4-point probe was used to assess the sheet resistance of
the materials (O sq1). The sheet resistance of the uncured
silver ink was 0.51  0.04 O sq1, which increased after curing
to 3.56  0.59 O sq1; the silver paint used within/on the MEAs
had an average resistance of 26.73  6.62 O sq1 if uncured,
and 0.70  0.04 O sq1 after curing; and the average resistance
of the silver painted and cured MEA channels was found to be
1.81  0.46 O sq1. By comparison, the average sheet resistance of
the MEAs filled with CNTs/PDMS was found to be 152 29 kO sq1.
The through channel conductivity of the silver electrodes
is 3.7  0.2 S cm1 and for the CNTs/PDMS electrodes it is
0.5  0.3 mS cm1.
Simple and effective sterilization methodologies for bespoke
MEAs would help enable their storage and potential reuse.
Sterilisation by exposure to ethylene oxide (EO) and gamma-
irradiation sterilization are effective methodologies, but were
ruled out due to their inaccessibility in many laboratories and
slow processing for EO.65 Autoclaving with high pressure
saturated steam at 121 1C for 20 min was ruled out as the
steam might hydrolyse the backbone of the PLA used to print
the MEA templates with channels; dry heat autoclaving (at 160–
170 1C for 20 min) was ruled out because the temperature is
similar to the melting point of PLA (although thermogravimetric
analysis demonstrated the onset of decomposition of the poly-
mer was significantly higher, as per Fig. S4 and S5, ESI†). The
MEAs produced were stable to brief exposure to aqueous ethanol or
aqueous isopropanol followed by UV irradiation, which represents
a pragmatic solution for laboratories undertaking electro-
physiology studies in vitro and ex vivo in academic and non-
academic environments.
Measurements of the force required to break the MEAs were
undertaken using an experimental paradigm replicating an
individual holding the MEA with their index and middle finger
beneath it while applying pressure to the top surface with their
thumb, based on studies finding forces of up to 179 N exerted
using index fingers, and up to 290 N exerted using thumbs.66
We observed the MEAs were robust towards the likely external
forces acting upon them using a three-point flexural load
testing model (Fig. S6, ESI†) and shear testing (Fig. S7, ESI†).
The stability of the electrical and chemical properties of the
prototype silver MEAs was assessed by immersion of the MEAs
in PBS for a period of 2 weeks which is significantly longer than
their use is envisioned. The average impedance of the MEA
tracks were very consistent over the period of the experiment,
confirming the stability of the electrical properties of the
electrode arrays (Fig. 2). Likewise, ICP-OES confirmed that no
leaching of the Ag was observed over the period of the experi-
ment (Fig. 2).
To validate the efficacy of the prototype MEAs for being able
to apply a stimulus in biological applications, the ability of the
MEAs to interact with a slice of mouse brain ex vivo resulting in
controlled stimulation of a neuronal pathway was assessed. An
acute brain slice was placed onto the MEA, which was then
used to deliver an electrical stimulus to CA3 efferent axons. To
verify that action potentials had successfully been activated
resulting in synaptic transmission, a postsynaptic response
(fEPSP) was then recorded, using a conventional glass electrode
placed amongst the proximal apical dendrites of CA1 pyramidal
neurones.67,68 Constant voltage stimulation via the silver contact
MEAs evoked fEPSPs, with a good signal-to-noise ratio, although
with a wide stimulus artefact (Fig. 3).
Typical of CA3-CA1 synapses, fEPSPs displayed paired-pulse
facilitation, whereby two identical stimuli in quick succession
gives rise to a larger response on the second stimulation. The
mean  standard error of the paired-pulse ratio recorded over a
10 min period was 1.25  0.04, indicative of the low probability
of neurotransmitter (glutamate) release expected in healthy
brain tissue.69 Over the 10 min period, the slope of the first
fEPSP was stable (calculated using WIN-WCP, Fig. S8, ESI†).
A tetanic conditioning stimulus train was then applied. Imme-
diately following tetanus, the slope of the first fEPSPs increased
in size and remained 4170% of the average baseline response
for the first 2 min post-tetanus. This initial increase is known as
post-tetanic potentiation and is mediated by an increase in
probability of glutamate release caused by unbuffered calcium in
the presynaptic terminal. The increased probability of release
was reflected by a decreased paired-pulse ratio (0.65  0.2), as
paired-pulse ratio is inversely proportional to probability of
release. By 3 min, the fEPSPs were 120–150% of baseline and
remained so for the rest of the experiment. This is short-term
potentiation and the very earliest stages of long-term potentia-
tion, the best cellular mechanism to explain learning and
memory.69 Between 11–20 mins, the paired-pulse ratio had
recovered to 1.18  0.08, which is not significantly different
Fig. 2 Stability of the electrical and chemical properties of the prototype
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from baseline. Thus, little if any change in release probability
remained and the increase in fEPSP was mediated by postsynaptic
alterations, such as glutamate (AMPA) receptor phosphorylation or
extra AMPA receptors being inserted into the synapse.69 Finally, to
confirm the physiological basis of the responses, the voltage-gated
sodium channel blocker tetrodotoxin (TTX, 1 mM) was applied,
which blocks action potentials, thus preventing glutamate release.
In the presence of TTX, the fEPSP was abolished.
We further demonstrate in this proof of concept trial that
the silver-coated electrodes made contact more effectively than
the CNTs/PDMS contact MEAs. Despite the silicone electrodes
effectively producing electrical output as demonstrated by a
clear stimulus artefact in response to single or high-frequency
pulses (Fig. S9, ESI†), constant voltage stimulation failed to
result in a physiological response. The occurrence of a clear
stimulus artefact but no response (Fig. S9, ESI†) suggests poor
contact between the carbon nanotubes and the mouse brain
slice so the electrical output did not result in the stimulation of
the axon pathway. Stimuli ranging from 0–100 V and 2–100 ms
were tested. However, as demonstrated by the silver coated
electrodes, when optimised the MEA can be used in biological
situations requiring high-frequency stimulation, such as experi-
ments similar to that using the silver contact MEAs to induce
long-term potentiation (Fig. S9, ESI†) or any other situation
where repetitive stimuli applied to nerve tissue would be
desirable.
Conclusions
Herein we report an AM approach to the preparation of bespoke
MEAs for biotechnological applications. The MEAs with either
silver or CNTs/PDMS electrodes were characterized, as was their
ability to interact with a slice of mouse brain (ex vivo) on the
application of an electrical stimulus, yielding MEAs displaying
good signal-to-noise ratios. The cost of the silver contact MEAs
was calculated to be ca. d36 (ca. $47 US Dollars in January 2021)
per MEA (factoring in: substrate costs calculated using PolyJet
Studio, supplied with the Stratasys J750, including the cyan
material used with the support material to help with adhesion
and strength; from user experience, one syringe could be used
for two MEAs, with five needles being needed per MEA due to
clogging which was less problematic for a-terpineol formula-
tions), which we believe could be reduced if the MEAs were to
be manufactured in a more controlled environment (e.g. using
an automated channel filling process to increase the produc-
tion rate). This is cheaper than the price of MEAs currently
marketed that are manufactured by traditional methods,
mainly due to the reduction in the number of processes
involved in the AM process. Such prototype MEAs should be
able to be reused a few times to offer the user an opportunity to
hone their experiment and/or change the size/position of the
electrodes; however, while the CNTs and PDMS are stable over
prolonged periods, it is foreseeable that the PLA and silver will
degrade over time, consequently, we do not propose these
prototypes for indefinite use. Moreover we demonstrate the
importance of testing the particular type of electrode for the
proposed use. The AM process described here is specifically
designed for stimulation of nerve activity in biological tissues
but it could easily be adapted for recording signals or other
industrially relevant biotechnological applications (e.g. 3D
printed vessels with embedded electrodes to measure the
concentration of dissolved O2 and pH in high throughput
bioreactors, or biodegradable MEAs).70–74
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